Valuation: H&R GmbH & Co KgaA

Market Cap 271M 311M 256M 232M 435M 29.82B 437M 3.06B 1.18B 15.16B 1.17B 1.14B 48.78B P/E 2026 *
5.64x
P/E 2027 * 19.7x
Enterprise Value 294M 337M 277M 252M 472M 32.33B 474M 3.32B 1.28B 16.44B 1.27B 1.24B 52.9B EV / Sales 2026 *
0.21x
EV / Sales 2027 * 0.21x
Free-Float
21.97%
Yield 2026 *
0.69%
Yield 2027 * 0.69%
08-14 H&R GmbH & Co. KGaA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-15 H&R GmbH & Co. KGaA Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-31 H&R GmbH & Co. KGaA Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-28 Kepler Cheuvreux Favors BASF and Bayer, Avoids H&R and Evonik DP
11-14 H&R GmbH & Co. KGaA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-14 H&R GmbH & Co. KGaA Revises Earnings Guidance for the Full Year 2025 CI
25-08-24 Nils Hansen acquired additional 7.78% stake in H&R GmbH & Co. KGaA from Srs Schmierstoff Vertrieb GmbH, ÖLfabrik Wilhelm Scholten GmbH, Wilhelm Scholten Beteiligungen GmbH and others for ?15 million. CI
25-08-15 H&R GmbH & Co. KGaA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-15 Nils Hansen proposed to acquire remaining 38.55% stake in H&R GmbH & Co. KGaA from Srs Schmierstoff Vertrieb GmbH, ÖLfabrik Wilhelm Scholten GmbH, Wilhelm Scholten Beteiligungen GmbH and others for ?73 million. CI
25-05-13 H&R GmbH & Co. KGaA Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-04-16 H&R GmbH & Co. KGaA announces Annual dividend, payable on May 30, 2025 CI
25-04-08 H&R GmbH & Co. KGaA Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25-03-26 H&R GmbH & Co. KGaA Says Postponement Of The Publication Of The Consolidated Financial Statements And The Annual Report 2024 RE
Manager TitleAgeSince
Chief Executive Officer 61 2015-12-31
Investor Relations Contact - 2005-12-31
Director TitleAgeSince
Chairman 62 2012-04-16
Director/Board Member 71 2011-04-30
Director/Board Member 69 2011-04-30
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 311M
-1.26%-2.02%+2.78%+20.13% 121B
+0.85%+1.49%+544.99%+245.93% 58.66B
-0.08%-3.61%-20.92%-42.93% 38.33B
+1.17%-4.50%+8.00%-23.58% 32.83B
+1.55%-1.59%+40.92%+64.28% 25.19B
-3.61%-2.76%+17.54%-38.40% 20.76B
-0.62%-5.51%+37.58%+4.47% 18.45B
-1.38%-16.76%+26.94%+302.20% 17.78B
+0.24%-4.92%-1.26%+11.10% 17.19B
Average -0.31%-3.71%+72.95%+60.36% 38.88B
Weighted average by Cap. -0.38%-2.55%+98.05%+59.74%

Financials

2026 *2027 *
Net sales 1.4B 1.6B 1.32B 1.2B 2.24B 154B 2.25B 15.78B 6.09B 78.07B 6.01B 5.88B 251B 1.36B 1.56B 1.29B 1.17B 2.19B 150B 2.2B 15.41B 5.95B 76.22B 5.87B 5.74B 245B
Net income 48.09M 55.15M 45.41M 41.23M 77.26M 5.29B 77.58M 544M 210M 2.69B 207M 203M 8.66B 13.79M 15.81M 13.02M 11.82M 22.15M 1.52B 22.24M 156M 60.18M 771M 59.4M 58.08M 2.48B
Net Debt 22.87M 26.22M 21.59M 19.61M 36.74M 2.52B 36.89M 259M 99.81M 1.28B 98.51M 96.32M 4.12B 8.65M 9.92M 8.17M 7.42M 13.9M 952M 13.96M 97.84M 37.76M 484M 37.27M 36.44M 1.56B
Logo H&R GmbH & Co KgaA
H&R GmbH & Co KGaA is a Germany-based manufacturing of chemical and pharmaceutical speciality products. The Company’s two business activities are chemicals and pharmaceutical raw materials and precision plastic parts. It operates through three segments: ChemPharm Refining, ChemPharm Sales and Plastics. The ChemPharm Refining segment, which produces oils, technical and medical white oils as well as paraffins and wax products; the ChemPharm Sales segment, which produces plasticizers and wax emulsions and the Plastics segment manufacturing precision plastic parts as well as assemblies and medical consumables.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!